Piper Sandler Reiterates Overweight on Moderna, Maintains $214 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has reiterated an Overweight rating on Moderna (NASDAQ:MRNA) and maintained a price target of $214.
June 27, 2024 | 3:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler analyst Edward Tenthoff has reiterated an Overweight rating on Moderna and maintained a price target of $214.
The reiteration of an Overweight rating and a maintained price target of $214 by a reputable analyst can boost investor confidence in Moderna, potentially leading to a short-term increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100